For primary hyperlipidemia. ANDA 202190, held by Glenmark Pharms Ltd. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 202190 (Colesevelam Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Jul 16, 2018, with 5 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride for oral suspension is a bile acid sequestrant indicated as an adjunct to diet and exercise to:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2018 | Original application | Approved |
| Colesevelam Hydrochloride1.875GM/PACKET · for suspension;oral | Colesevelam Hydrochloride | Rx |
| Colesevelam Hydrochloride3.75GM/PACKET · for suspension;oral | Colesevelam Hydrochloride | Rx |
| Nov 2, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 28, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 31, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 16, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters